Shattuck Labs, Inc. (NASDAQ:STTK) Short Interest Update

Shattuck Labs, Inc. (NASDAQ:STTK) saw a significant growth in short interest during the month of December. As of December 31st, there was short interest totaling 1,028,366 shares, a growth of 38.5% from the December 15th total of 742,537 shares. Based on an average daily trading volume, of 452,295 shares, the days-to-cover ratio is presently 2.3 days. Currently, 1.8% of the company’s shares are sold short. Currently, 1.8% of the company’s shares are sold short. Based on an average daily trading volume, of 452,295 shares, the days-to-cover ratio is presently 2.3 days.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on STTK shares. Citigroup boosted their price target on shares of Shattuck Labs from $2.00 to $4.00 and gave the company a “neutral” rating in a research note on Tuesday, January 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Shattuck Labs in a report on Wednesday, October 8th. Finally, HC Wainwright upgraded Shattuck Labs from a “neutral” rating to a “buy” rating and set a $6.00 price target on the stock in a research note on Monday, December 1st. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $4.00.

Shattuck Labs Stock Performance

Shares of NASDAQ:STTK traded up $0.17 during trading on Friday, hitting $4.64. The company’s stock had a trading volume of 485,596 shares, compared to its average volume of 617,574. Shattuck Labs has a fifty-two week low of $0.69 and a fifty-two week high of $4.89. The business has a 50 day moving average price of $3.07 and a two-hundred day moving average price of $2.03. The company has a market capitalization of $293.62 million, a PE ratio of -4.55 and a beta of 1.53.

Shattuck Labs (NASDAQ:STTK) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.01. The company had revenue of $1.00 million during the quarter. As a group, equities analysts expect that Shattuck Labs will post -1.48 earnings per share for the current fiscal year.

Institutional Trading of Shattuck Labs

A number of large investors have recently made changes to their positions in STTK. Turtle Creek Wealth Advisors LLC acquired a new position in shares of Shattuck Labs in the 3rd quarter valued at $29,000. Virtu Financial LLC acquired a new position in Shattuck Labs in the third quarter valued at $38,000. AQR Capital Management LLC grew its holdings in shares of Shattuck Labs by 265.4% during the first quarter. AQR Capital Management LLC now owns 43,169 shares of the company’s stock worth $41,000 after purchasing an additional 31,355 shares during the last quarter. Qube Research & Technologies Ltd purchased a new position in shares of Shattuck Labs during the second quarter worth about $44,000. Finally, Squarepoint Ops LLC acquired a new stake in shares of Shattuck Labs during the third quarter worth about $46,000. 58.74% of the stock is currently owned by hedge funds and other institutional investors.

Shattuck Labs Company Profile

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.